Latest Regulatory News

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Amplitude Energy has delivered a standout half-year performance with record gas production and a 246% jump in profit, while advancing key projects and strengthening its balance sheet.

Forrestania Resources has agreed to acquire multiple gold exploration tenements from Flynn Gold, consolidating its position in the highly prospective Forrestania Hub of Western Australia. The deal supports Forrestania’s growth strategy and near-term production goals.

Doctor Care Anywhere has reported its first profitable year, driven by a 6.5% revenue growth and improved margins, setting the stage for accelerated growth in 2026. The telehealth provider reaffirms ambitious medium-term targets amid operational enhancements and new clinical pathways.

AuMEGA Metals has confirmed a $30 million oversubscribed financing led by Condire Investors to fund expanded drilling and exploration in Newfoundland. The capital raise is structured in two tranches, with the first closing expected in early March and the second pending shareholder approval.

Pacgold has secured a profit share agreement to tap into the high-grade, historically mined Wadnaminga Project near its White Dam operations, aiming to fast-track gold production from legacy tailings and untested lodes.

NextEd Group Limited reported a 16.7% rise in underlying EBITDA and a 92% reduction in NPAT loss for H1 FY26, underpinned by AI integration and a strategic shift to higher-margin education segments.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Eminence Minerals Limited has issued 2.7 million unquoted CEO performance rights as part of a new executive appointment, utilising its 15% placement capacity without shareholder approval.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

SolGold shareholders have approved the recommended cash acquisition by Jiangxi Copper, a move that directly impacts DGR Global’s substantial investment in the company. Completion awaits court approval and further conditions.

Foresta Group Holdings reported a 12% increase in its half-year loss to nearly $2 million as it progresses its pioneering wood pellet and pine chemicals project in New Zealand, securing key lease agreements and finalising a $2.4 million insurance settlement.